The Stevanato Group
Stevanato Group (NYSE: STVN) is a vertically integrated Italian manufacturer of glass primary packaging (vials, syringes, cartridges, ampoules) and proprietary drug delivery devices (autoinjectors, pen injectors, on-body systems) serving global pharmaceutical, biotechnology, and life sciences companies through direct enterprise sales.
- Company typePublic
- Founded1949
- HeadquartersVeneto, Italy
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What The Stevanato Group does
Stevanato Group S.p.A. (NYSE: STVN) is a vertically integrated Italian pharmaceutical packaging manufacturer founded in 1949 in Piombino Dese, Italy. The company produces glass primary packaging — vials, syringes, cartridges, and ampoules — alongside proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system. Its flagship EZ-fill® platform provides pre-sterilized, ready-to-use containers that eliminate in-house washing and sterilization steps for pharmaceutical customers, with the platform licensed to multiple competitors including Gerresheimer and SGD Pharma, establishing it as an industry standard.
The company's revenue is generated across five streams: Drug Containment Solutions (vials, syringes, cartridges, ampoules in bulk and RTU formats — the core business, with high-value solutions at ~47-49% of revenue); Drug Delivery Systems (proprietary devices and contract manufacturing, driven by GLP-1 demand); Engineering (glass converting equipment, visual inspection, assembly, packaging, serialization — a lower-margin segment experiencing recent declines); In-Vitro Diagnostics & Medical Solutions; and Analytical & Testing Services through SG Lab. Stevanato serves global pharmaceutical, biotechnology, and life sciences companies on a direct enterprise field sales basis, with particular focus on biologics/mAbs, GLP-1/incretin therapies, vaccines, RNA-based drugs, and antibody-drug conjugates.
The company operates nine production plants across Italy, Denmark, Slovakia, Mexico, China, Brazil, the United States, Germany, and Romania, with 4,000+ employees and a backlog supporting revenue visibility. FY2025 revenue reached €1.186 billion (~7% YoY growth, 9% constant currency) with adjusted EBITDA margin of 25.1%, and management guides to €1.26-1.29 billion in FY2026. The business model is B2B direct sales with quote/procurement-based pricing to pharmaceutical manufacturers, anchored by long regulatory validation cycles that create switching costs.
The Stevanato Group firmographics
Firmographics- Name
- The Stevanato Group
- Legal name
- Stevanato Group S.p.A.
- Website
- https://stevanatogroup.com
- Company type
- Public
- Founded year
- 1949
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Stevanato Group (NYSE: STVN) is a vertically integrated Italian manufacturer of glass primary packaging (vials, syringes, cartridges, ampoules) and proprietary drug delivery devices (autoinjectors, pen injectors, on-body systems) serving global pharmaceutical, biotechnology, and life sciences companies through direct enterprise sales.
- Ownership category
- akta.pro rank
The Stevanato Group industry classification
Industry- Product category
- Pharmaceutical Packaging
- NAICS
- Glass Container Manufacturing (327213), Surgical Appliance and Supplies Manufacturing (339113), Glass and Glass Product Manufacturing (3272)
- SIC
- Glass Containers (3221), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)
- akta.pro secondary industries
- Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Pharmaceutical & Medical Plastic Packaging Manufacturing (IMANAEAK)
Keywords
Where The Stevanato Group is headquartered
LocationHeadquarters
- HQ city
- Veneto
- HQ country
- Italy
- HQ region
- Europe
Offices12 records
Markets served
The Stevanato Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Drug Containment Solutions: Glass primary packaging including vials, syringes, cartridges, and ampoules for pharmaceutical use, both in bulk and sterile RTU formats. This is the core revenue driver, with high-value solutions (HVS) comprising approximately 47-49% of total revenue. Includes proprietary EZ-fill platforms.
- Drug Delivery Systems: Proprietary devices including pen injectors (Alina®, Deora™), autoinjectors (Aidaptus®), and on-body delivery systems (Vertiva®), along with contract manufacturing of drug delivery devices. Growing segment driven by GLP-1 and incretin-based therapies.
- Engineering Segment: Equipment and technology for glass conversion, visual inspection, assembly, packaging, and serialization for pharmaceutical manufacturing. Includes after-sales services and support. Lower margin segment experiencing recent declines.
- In-Vitro Diagnostics & Medical Solutions: Point-of-care devices, IVD consumables, and medical solutions including customer-specific developments.
- Analytical & Testing Services: Chemical analysis, container interaction studies, surface characterization, container performance testing, drug delivery systems testing, and R&D fill-finish services through SG Lab.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
The Stevanato Group product offering
Product offeringCore offering
Stevanato Group manufactures and supplies integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Its offerings span glass primary packaging (vials, syringes, cartridges, ampoules) under proprietary platforms such as EZ-fill®, EZ-fill Smart®, Alba®, Nexa® and Fina®; proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system; AI-powered visual inspection equipment and glass converting machinery; plus analytical and testing services through SG Lab.
Product overview
Stevanato Group is a leading global provider of integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company operates across two main divisions: Pharmaceutical Systems (drug containment and delivery) and Engineering Systems (equipment and inspection). The product portfolio centers on glass primary packaging (vials, syringes, cartridges, ampoules) across platforms including EZ-fill®, EZ-fill Smart®, Alba®, Nexa®, and Fina®, combined with drug delivery devices (Aidaptus® autoinjector, Alina® and Deora™ pen injectors, Vertiva® on-body system), visual inspection systems with AI-powered defect detection, glass converting equipment, device assembly lines, and comprehensive analytical/testing services. The company delivers an integrated, end-to-end offering from drug containment to delivery systems and quality assurance.
Differentiator
Problem solved
Functional benefit
Brands
- EZ-fill: Pre-sterilized drug containment solutions platform including vials, syringes, and cartridges that reduce total cost of ownership and time-to-market
- EZ-fill Smart
- Nexa
- Alba
- Fina
- Aidaptus
- Alina
- Deora
- Vertiva
- SG Lab
- Ompi EZ-fill
Products and services
- EZ-fill® Platform (including EZ-fill Smart® and EZ-fill® Kit variants)
Quantifiable outcome
- High-Value Solutions (HVS) segment grew 17% year-over-year to €128.6 million in Q1 2026, comprising 47% of group sales
- +7 more outcomes
Companies that use The Stevanato Group
Customer profileNamed customers3 records
Segments6 records
Ideal customer profiles3 records
The Stevanato Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature15 records
The Stevanato Group partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor, core and strategic.
- Ypsomed AGminorJoint presentation at PDA Japan Combination Product Seminar 2026 on 'Optimizing injectability of high-viscosity biologics in next-generation syringe-based autoinjectors', with speakers from both Stevanato Group and Ypsomed.
- DatwylercoreThree-way collaboration with Datwyler and LTS Device Technologies to expand large-volume subcutaneous drug delivery, combining Datwyler's NeoFlex plungers, Stevanato's EZ-fill Large Volume Cartridges, and LTS's Sorrel wearable delivery platform into a pre-verified ecosystem for at-home administration of high-dose therapies (up to 20mL) including monoclonal antibodies and oncology drugs. Showcased at Pharmapack Paris in January 2026. Driven by patient preference data showing 73% favor at-home self-administration after 24 weeks of therapy.
- LTS Device TechnologiescoreThree-way collaboration enabling on-body self-administration of large-volume drugs up to 20mL by combining LTS's Sorrel wearable delivery platform with Stevanato's EZ-fill Large Volume Cartridges and Datwyler's NeoFlex plungers. Addresses growing demand for at-home biologic treatments with pre-verified platform solution aimed at accelerating pharmaceutical manufacturers' market access.
- Gerresheimer AGstrategicCollaborative session at CPHI 2025 featuring Gerresheimer and Stevanato Group joint capabilities, highlighting synergies in RTU potential, primary packaging innovations, and scalable fill-finish solutions. Gerresheimer showcased products including the EZ-fill Smart RTU platform and Gx InPuls on-body device.
- Haselmeier (medmix group)coreExtended licensing agreement for Axis-D pen injector technology giving Stevanato Group exclusivity to offer the technology for a broader range of therapeutic areas beyond diabetes, including obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, and arthritis. Basis for Alina® pen injector platform.
- Corning IncorporatedstrategicCollaboration agreement for supply of Corning Valor Glass—an enhanced pharmaceutical glass with superior chemical durability, strength, and damage resistance. Valor Glass addresses modern drug formulations and manufacturing processes, providing stronger and more chemically durable packaging to better protect drug products including life-saving medicines and vaccines.
- Toxikon EuropestrategicPartnership agreement for extractables and leachables analysis services. SG Lab combines its glass testing, physical testing, and container/closure integrity testing capabilities with Toxikon's expertise in extractables & leachables testing, toxicological assessments, and biocompatibility testing. Provides pharmaceutical companies with comprehensive analytical services for regulatory compliance across FDA and EMA requirements.
- Gerresheimer AGstrategicLicense agreement making Gerresheimer a partner on the Ompi EZ-fill® platform, reaffirming EZ-fill as the worldwide proven standard in processing sterile glass vials and cartridges. This validates the EZ-fill platform and extends its reach through Gerresheimer's global distribution network.
- Tip-TopstrategicLicensing agreement for safety needlestick protection platform technology enabling Ompi EZ-fill® ISS (Integrated Safety System) for prefilled syringes. The safety system prevents needlestick injury post-injection through a passive locking mechanism. All plastic components are designed and produced by Balda, a Stevanato Group company.
- SGD PharmastrategicSGD Pharma became the first molded glass supplier to join the Ompi EZ-fill® platform, offering sterile and depyrogenated RTU molded vials. Validates EZ-fill as a platform standard extending beyond Stevanato's own products.
Scale indicators19 records
Recent moves15 records
Expansion highlights6 records
The Stevanato Group competitors and assessment
Company assessmentDirect peers
- Gerresheimer AG: German-headquartered global manufacturer of pharmaceutical glass and plastic packaging plus drug delivery devices; a direct competitor in primary packaging and an EZ-fill® licensee.
- SCHOTT Pharma AG & Co. KGaA: Subsidiary of SCHOTT AG and leading producer of pharmaceutical glass vials, syringes, cartridges, and ampoules; competes head-to-head with Stevanato in primary containment for injectables.
- SGD Pharma: French manufacturer of molded and tubular glass pharmaceutical packaging; joined the EZ-fill® platform as the first molded-glass licensee, making it both a partner and direct competitor.
- Ypsomed AG: Swiss manufacturer of injection systems (pen injectors and autoinjectors) and a direct Stevanato co-development partner via joint presentations on high-viscosity biologics autoinjectors.
- Dätwyler Holding AG: Swiss manufacturer of elastomer components and plunger/seal systems for injectable drug packaging; a Stevanato partner on EZ-fill® Large Volume Cartridge ecosystems (NeoFlex plungers).
- Nipro Corporation: Japanese medical device and pharmaceutical glass manufacturer producing glass tubing, vials, syringes, and dialyzers; competes directly with Stevanato in primary packaging for injectables, particularly in Asia.
Broad incumbents
- West Pharmaceutical Services: US-based global leader in elastomeric closures, seals, and drug delivery components for injectables; competes with Stevanato's containment and delivery offering from an adjacent, broader component portfolio.
- AptarGroup, Inc. US-based global supplier of drug delivery devices, dispensing closures, and active material solutions; competes in elastomeric/injectable delivery components and broader pharma packaging.
- Becton, Dickinson and Company (BD): Global medical technology incumbent with a large pharmaceutical systems segment offering prefilled syringes, drug delivery devices, and injection systems; overlaps with Stevanato across containment and delivery.
- Corning Incorporated: Supplier of Corning Valor Glass to Stevanato under collaboration agreement; also a broader competitor in pharmaceutical glass with deep US manufacturing footprint and direct federal relationships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
The Stevanato Group social profiles
Digital presenceThe Stevanato Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Stevanato Group leadership team
Management profileNumber of profiles
Profiles12 records
The Stevanato Group subsidiaries and ownership
Company hierarchySubsidiaries9 records
The Stevanato Group funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Stevanato Group M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Stevanato Group
What does The Stevanato Group do?
Stevanato Group manufactures and supplies integrated drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Its offerings span glass primary packaging (vials, syringes, cartridges, ampoules) under proprietary platforms such as EZ-fill®, EZ-fill Smart®, Alba®, Nexa® and Fina®; proprietary drug delivery devices including the Aidaptus® autoinjector, Alina® and Deora™ pen injectors, and Vertiva® on-body delivery system; AI-powered visual inspection equipment and glass converting machinery; plus analytical and testing services through SG Lab.
Is The Stevanato Group a public or private company?
The Stevanato Group is a public company. It is classified as public and is currently operating.
When was The Stevanato Group founded?
The Stevanato Group was founded in 1949. It employs 5,001 to 10,000 people.
Where is The Stevanato Group based?
The Stevanato Group is headquartered in Veneto, Italy, in the Europe region.
How does The Stevanato Group make money?
Five revenue lines are on record. Drug Containment Solutions are the primary driver. The others are drug Delivery Systems, engineering Segment, in-Vitro Diagnostics & Medical Solutions and analytical & Testing Services.
Who are The Stevanato Group's main competitors?
Direct peers on record are Gerresheimer AG, SCHOTT Pharma AG & Co. KGaA, SGD Pharma, Ypsomed AG, Dätwyler Holding AG and Nipro Corporation. Broad incumbents are West Pharmaceutical Services, AptarGroup, Inc., Becton, Dickinson and Company (BD) and Corning Incorporated.
Does The Stevanato Group have an API?
No public API is recorded for The Stevanato Group.
What industry is The Stevanato Group in?
The Stevanato Group's product category is Pharmaceutical Packaging. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules), with a secondary code of IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes). Its NAICS code is 327213 and its SIC code is 3221.